

Remarks

In response to the outstanding Official Action, the claims have been amended in a manner that is believed to obviate all objections and rejections.

In particular, the misspellings of deoxycytidine in claims 24 and 42 has been corrected.

A number of claims were rejected under 35 USC §112, second paragraph, as indefinite. In accordance with the Examiner's kind suggestion, claims 22 and 32 have been amended to recite "in effective amounts", to indicate that the effective amounts are of both of the claimed agents.

Another indefiniteness rejection has been obviated by the amendment of claims 22 and 32 to recite the expanded names of PALA, FdC, 4-N-methyl FdC and FdU.

The only remaining issue was the rejection of claims 29, 31, 39 and 41 as failing to comply with the written description requirement. The claim terminology to a radiation source attached to a monoclonal antibody has been deleted from these claims, in order to obviate this issue. It is noted that these radiation sources are encompassed by the generic claims in this application.


An opportunity has been taken to correct a typographical error appearing in claims 30 and 40 with respect to the spelling of "iridium". This correction is supported, for instance, by original claim 9.

The applicant thanks the Examiner for the kind suggestions in the outstanding Office Action. As a sincere effort has been made to follow these

suggestions, it is believed that the present application is in proper condition for allowance, and an early notice to that effect is solicited.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 02-2135.

Respectfully submitted,

By 
Robert B. Murray
Attorney for Applicants
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

RBM/cb